Abstract
The overall annual incidence of phaeochromocytoma is 6 per one million population [1]. MPCs account for only 10 % of all phaeochromocytomas and mostly occur in the 30–40-year age group. Clinically, MPCs like their benign counterparts present with paroxysmal hypertension, headaches, palpitations, etc. The suspicion of malignancy will be raised by the persistence of the signs and symptoms, as well as the elevated values of plasma and urinary methoxyamines after surgical excision of the tumour. The histopathological features of malignancy are controversial and not specific.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 2007;92(4):1217–25.
Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ, Pacak K. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48(11):1739–49.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Al-Mamari, S.A., Al-Busaidy, S.S. (2015). Malignant Phaeochromocytoma (MPC). In: Al-Mamari, S., Al-Busaidy, S. (eds) Urological Cancer Management. Springer, Cham. https://doi.org/10.1007/978-3-319-16301-7_28
Download citation
DOI: https://doi.org/10.1007/978-3-319-16301-7_28
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16300-0
Online ISBN: 978-3-319-16301-7
eBook Packages: MedicineMedicine (R0)